• Welcome to Hair loss Experiences hair loss forum.

    Free impartial hair loss advice, hair transplant advice, hair loss medications and hair loss news.
    You can contact us directly at [email protected] if you experience any problems.




Staff member
ICX-TRC is an autologous hair regeneration therapy intended for the treatment of male pattern baldness and female diffuse alopecia.

A small sample of hair follicles is taken from the patient during a simple 30 minute operation carried out under local anaesthetic at a hair or skin clinic. The clinic will send the biopsy to Intercytex €™ manufacturing facility where the hair-inductive dermal papilla cells are dissociated from the rest of the follicle. These cells are cultured and expanded in proprietary media over three weeks and subsequently returned to the clinic in a sterile suspension. Using a specialised delivery system, the hair-inductive dermal papilla cells are microinjected intradermally into the patient €™s scalp. The treatment is performed under local anaesthetic and comprises a single procedure of superficial injections, each injection delivering a minute volume of media containing dermal papilla cells capable of inducing new hair growth. Following the procedure, new hair growth should become evident after approximately three months.

It is intended that ICX-TRC will be used by specialists in hair transplant centres, dermatologists and plastic surgeons to treat patients with hair thinning or hair loss.

Intercytex will initially develop ICX-TRC to treat male pattern baldness and expand the indication to include treatment of female diffuse alopecia.

Phase I clinical trials (safety) have been completed in seven volunteers at a single UK transplant centre. No safety issues have arisen and five out of the seven patients have shown increased hair numbers. A Phase II clinical efficacy trial on patients with male pattern baldness is planned to commence in the first half of 2006.